Table 3 Analysis of characteristics of gastric complications in breast cancer patients [n(%)]
Gastric side effects | χ2-value/t value | P-value | ||
|---|---|---|---|---|
No (%) | Yes (%) | |||
Age | 0.91 | 0.367 | ||
47.5 ± 8.1 | 49.6 ± 10.8 | |||
T stage | 1.50 | 0.682 | ||
T1 | 48 (88.9) | 6 (11.1) | ||
T2 | 47 (87.0) | 7 (13.0) | ||
T3 | 8 (80.0) | 2 (20.0) | ||
T4 | 6 (100.0) | 0 (0.0) | ||
N stage | 1.35 | 0.279 | ||
N0 | 48 (84.2) | 9 (15.8) | ||
N1, N2, N3, Nx | 61 (91.0) | 6 (9.0) | ||
Hormone receptor (±) | 0.78 | 0.355 | ||
Negative | 25 (83.3) | 5 (16.7) | ||
Positive | 84 (89.4) | 10 (10.6) | ||
HER2 | 0.03 | 1.000 | ||
Negative | 75 (88.2) | 10 (11.8) | ||
Positive | 34 (87.2) | 5 (12.8) | ||
Breast conserving surgery (yes/no) | 0.46 | 0.585 | ||
No | 48 (85.7) | 8 (14.3) | ||
Yes | 61 (89.7) | 7 (10.3) | ||
Fractionated regimen | 1.47 | 0.273 | ||
Conventional radiotherapy | 47 (92.2) | 4 (7.8) | ||
Hypofractionated radiotherapy | 62 (84.9) | 11 (15.1) | ||
Chemotherapy (yes/no) | 0.01 | 1.000 | ||
No | 23 (88.5) | 3 (11.5) | ||
Yes | 86 (87.8) | 12 (12.2) | ||
Stomach volume (m3) | 2.01 | 0.047 | ||
371.6 ± 149.1 | 458.5 ± 209.4 | |||
Use of respiratory gating technique | 5.17 | 0.026 | ||
DIBH | 48 (96.0) | 2 (4.0) | ||
FB | 61 (82.4) | 13 (17.6) | ||
Dmax/F | 9.44 | 0.000 | ||
122.5 ± 89.8 | 241.8 ± 35.8 | |||
D10cc/F | 6.34 | 0.000 | ||
63.3 ± 63.4 | 174.1 ± 63.6 | |||
D30cc/F | 4.27 | 0.001 | ||
34.4 ± 38.8 | 114.2 ± 71.0 | |||
D60cc/F | 3.98 | 0.001 | ||
18.7 ± 20.2 | 69.8 ± 49.2 |